Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis
Background Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature. Methods A total sample of 202 patients were retrospectively reviewed at the University...
Saved in:
Main Authors: | Yousuf Zafar (Author), Yasar Sattar (Author), Waqas Ullah (Author), Sohaib Roomi (Author), Mamoon- (Author), Muhammad Shayan Khan (Author), Laura Schmidt (Author) |
---|---|
Format: | Book |
Published: |
Greater Baltimore Medical Center,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Proprotein Convertase Subtilisin Kexin Type 9 (PCSK9) Beyond Lipids: The Role in Oxidative Stress and Thrombosis
by: Vittoria Cammisotto, et al.
Published: (2022) -
The role of proprotein convertase subtilisin-kexin type 9 (PCSK9) in the vascular aging process - is there a link?
by: Malwina Grobelna, et al.
Published: (2019) -
Treatment with Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i): Current Evidence for Expanding the Paradigm?
by: Rosaria Vincenza Giglio BD, PhD, et al.
Published: (2023) -
Lipid-lowering interventions targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): an emerging chapter in lipid-lowering therapy
by: Constantine E Kosmas, et al.
Published: (2017) -
The history of proprotein convertase subtilisin kexin-9 inhibitors and their role in the treatment of cardiovascular disease
by: Eun Ji Kim, et al.
Published: (2020)